Drug intelligence / Profile preview

PSY-05

Development stage: Preclinical
Lead developer: Psy Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

PSY-05 (also referred to as PSY-05001) is a small molecule therapeutic being developed by Psy Therapeutics for the treatment of neuropsychiatric and pain disorders. It is currently in the IND-enabling phase for several indications, including General Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), and both subacute and chronic pain. The drug is designed to address significant unmet needs in mental health and pain management, although its specific biological target and molecular mechanism of action have not been publicly disclosed in the company's pipeline documentation.

Beyond the preview

Go deeper on PSY-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSY-05.

Explore the full profile